Treatment of rhabdoid tumors with ONO-4538

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy and safety of ONO-4538, a novel treatment, in patients suffering from rhabdoid tumors. It focuses on individuals who have advanced or recurrent forms of this rare cancer and have not responded to standard chemotherapy regimens. The trial aims to assess how well this new intervention works in managing the disease and improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Gender: Not specified
2. Age (at the time of consent): 1 year or older
3. Patients who are refractory or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors
4. Patients with advanced or recurrent rhabdoid Tumors not eligible for curative resection

Exclusion Criteria:

1. Patients with a history of active concurrent malignancy or complications
2. Patients with spinal lesions expected to require radiation therapy or surgical intervention during the trial period
3. Patients with concomitant central nervous system disorders other than AT/RT that are inadequately controlled or may lead to discontinuation of the investigational drug

Where it's running

• Nagoya University Hospital
  Nagoya, Aichi-ken, Japan Recruiting
• Hokkaido University Hospital
  Sapporo, Hokkaido, Japan Recruiting
• Hyogo Prefectural Kobe Children's Hospital
  Kobe, Hyōgo, Japan Recruiting
• Osaka City General Hospital
  Osaka, Osaka, Japan Recruiting
• National Cancer Center Hospital
  Chuo-ku, Tokyo, Japan Recruiting
• Chiba University Hospital
  Chiba, Japan Recruiting

Study contacts

• Study coordinator: North America Clinical Trial Support Desk
• Email: clinical_trial@ono-pharma.com
• Phone: +18665877745(Toll-Free)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Testing selinexor for treating Wilms tumors and other solid tumors

  This study is testing if selinexor can help children with certain hard-to-treat tumors, like Wilms tumors, feel better and improve their health.

  Recruiting at 16 sites Phase 2 Memorial Sloan Kettering Cancer Center · Los Angeles, California and 15 other locations · NCT05985161

• B7-H3 CAR T-cell therapy for pediatric solid tumors

  This study is testing a new type of immune therapy using specially modified T cells to see if it can help children with tough-to-treat solid tumors.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04897321

• GPC3-targeted CAR T cells armored with IL-15 and IL-21 for pediatric non‑CNS solid tumors

  This treatment will try personalized CAR T cells that target GPC3 and are engineered to make IL‑15 and IL‑21 in children and young adults with relapsed or refractory non‑CNS solid tumors that express GPC3.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT07148050

• IL-15 and IL-21–armored GPC3-CAR T cell therapy for adults with GPC3-positive solid tumors

  This trial tests whether CAR T cells engineered to target GPC3 and fortified with IL-15 and IL-21 can treat adults with GPC3-positive liver and other solid tumors.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT06198296

• Using engineered T cells to treat pediatric solid tumors

  This study is testing a new treatment using specially modified immune cells to see if they can help children with certain types of solid tumors, like liver cancer and rhabdomyosarcoma, feel better.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT04715191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.